Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03780049 Recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

Hepatic artery infusion chemotherapy (HAIC) is effective and safe for hepatocellular carcinoma (HCC). Recombinant Human Type-5 Adenovirus (H101) is safe for HCC. The purpose of this study is to evaluate the efficacy and safety of HAIC combined with H101 compared with HAIC alone in patients with unresectable hepatocellular carcinoma (HCC) at barcelona clinic liver cancer A-B stage.

NCT ID: NCT03777475 Recruiting - Clinical trials for Hepatocellular Carcinoma

the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular Carcinoma

Start date: July 1, 2016
Phase: N/A
Study type: Interventional

evaluate the effect of different oxaliplatin dose in TAI in treating unresectable HCC.

NCT ID: NCT03775395 Recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC

Start date: December 12, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with lenvatinib combined with HAIC in patients with advanced hepatocellular carcinoma (HCC)

NCT ID: NCT03754192 Recruiting - Clinical trials for Hepatocellular Carcinoma

Perfusion and Dual Energy Computer Tomography in Hepatocellular Carcinoma

PERCAHEC
Start date: January 30, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the hepatic perfusion computer tomography and dual energy computer tomography in the assessment of tumor characterization of Hepatocellular carcinoma in patients with resectable Hepatocellular carcinoma by comparing the quantitative parameters computer tomography obtained with the pathological data of the surgical specimens.

NCT ID: NCT03734926 Recruiting - Colorectal Cancer Clinical Trials

A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors

Start date: November 13, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1241 in participants with hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.

NCT ID: NCT03734068 Recruiting - Clinical trials for Hepatocellular Carcinoma

Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC

LIFDOX
Start date: June 13, 2018
Phase:
Study type: Observational

The aim of this study is to collect data on efficacy and tolerability on a large series of patient of different Italian hospitals in order to support the validation of LifePearl with robust and consistent clinical evidence. Since TACE in treating HCC is considered a more common and accepted approach, this study will be focused on evaluating treatment efficacy and safety of LIFDOX for un-resectable hepatocellular carcinoma.

NCT ID: NCT03732105 Recruiting - Clinical trials for Hepatocellular Carcinoma

Randomized Study of Adjuvant Radiotherapy After Curative Resection of HCC With Narrow Margin (RAISE)

RAISE
Start date: August 8, 2018
Phase: N/A
Study type: Interventional

RAISE is a multicenter randomized controlled trial to assess the efficacy of adjuvant radiotherapy for controlling postsurgical recurrence in HCC patients with narrow margin (≤ 1 cm) after curative resection.

NCT ID: NCT03731910 Recruiting - Clinical trials for Hepatocellular Carcinoma

Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE

Start date: December 11, 2018
Phase: N/A
Study type: Interventional

This study aims to investigate the value of early change at MRI in HCC treated with TARE, for evaluation/prediction of treatment response and prognosis.

NCT ID: NCT03730675 Recruiting - Clinical trials for Hepatocellular Carcinoma

Irradiation Stent Placement Plus TACE for HCC and PVTT

Start date: November 10, 2018
Phase: N/A
Study type: Interventional

The study is a multicenter, randomized (1:1), open-label, parallel-arm, Phase 3 clinical trial to evaluate the efficacy and safety of portal irradiation stent placement plus TACE compared to sorafenib plus TACE in patients with advanced HCC accompanied by portal vein tumor thrombosis. Patients will be randomized to receive either portal irradiation stent placement plus TACE(Arm A) or Sorafenib plus TACE (Arm B).

NCT ID: NCT03722875 Recruiting - Clinical trials for Hepatocellular Carcinoma

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

SHR-1210 is a humanized anti-PD1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label,single center ,non-randomized ,Single Arm Exploratory Study . This clinical study is an investigator-initiatedclini-cal trial(IIT ).The objective of this study is to evaluate the efficacy and safety of adjuvant therapy with anti-PD-1 antibody SHR-1210 and apatinib in patients with Barcelona Clinic Liver Cancer (BCLC) B&C stage hepatocellular carcinoma after surgery.